Hepatitis A Surveillance and Vaccine Use in China From 1990 Through 2007

被引:49
作者
Cui, Fuqiang [1 ]
Hadler, Stephen C. [2 ]
Zheng, Hui [1 ]
Wang, Fuzhen [1 ]
Wu Zhenhua [1 ]
Hu Yuansheng [1 ]
Gong, Xiaohong [1 ]
Chen, Yuansheng [1 ]
Liang, Xiaofeng [1 ]
机构
[1] Chinese Ctr Dis Control & Prevent, Beijing 100050, Peoples R China
[2] WHO Representat Off China, Beijing, Peoples R China
关键词
hepatitis A; epidemiology; surveillance; vaccine; IMMUNOGENICITY; IMMUNIZATION; H2-STRAIN; EFFICACY; OUTBREAK; CHILDREN; PROGRAM; SAFETY; ISRAEL; WATER;
D O I
10.2188/jea.JE20080087
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Hepatitis A vaccines have been highly effective in preventing hepatitis A. To investigate the epidemiology of hepatitis A in China after hepatitis A vaccine became available, we reviewed reported cases of hepatitis A and the use of hepatitis A vaccine in China during the period from 1990 through 2007. Methods: Data from the National Notifiable Disease Reporting System from 1990 to 2007 and the Emergency Events Reporting System from 2004 to 2007 were reviewed and epidemiologic characteristics analyzed. Hepatitis A vaccine distribution between 1992 and 2007 was also reviewed. Results: The incidence of hepatitis A has declined by 90% since 1990, from 56 to 5.9 per 10(5)/year. Declines in age-specific incidence were seen in all age groups, most dramatically among children younger than 10 years. Disease incidence still varies Substantially: poorer western provinces have had the highest incidences since 2000. In high-incidence provinces, children younger than 10 years continue to have a high disease incidence. Only 50% of cases were laboratory-confirmed, and only 3% occurred in reported local outbreaks. Over 156 million doses of hepatitis A vaccine have been distributed since 1992, and use has continued to increase since 2003. Conclusions: Incidence of hepatitis A has decreased in all age groups, likely due to changing socioeconomic conditions and increasing hepatitis A vaccine use. Nevertheless, western populations remain at high risk, with transmission predominantly occurring among children. The epidemiology of hepatitis A transmission is not well understood. Improved Surveillance with better laboratory confirmation is needed to monitor the impact of universal hepatitis A vaccination of young children; this strategy began to be implemented in 2008.
引用
收藏
页码:189 / 195
页数:7
相关论文
共 23 条
  • [11] The cost-effectiveness of universal vaccination of children against hepatitis A in Argentina: results of a dynamic health-economic analysis
    Lopez, Eduardo
    Debbag, Roberto
    Coudeville, Laurent
    Baron-Papillon, Florence
    Armoni, Judith
    [J]. JOURNAL OF GASTROENTEROLOGY, 2007, 42 (02) : 152 - 160
  • [12] MALLSEZAHL D, 1996, INT J EPIDEMIOL, V25, P1271
  • [13] Further evaluation of the safety and protective efficacy of live attenuated hepatitis A vaccine (H2-strain) in humans
    Mao, JS
    Chai, SA
    Xie, RY
    Chen, NL
    Jiang, Q
    Zhu, XZ
    Zhang, SY
    Huang, HY
    Mao, HW
    Bao, XN
    Liu, CJ
    [J]. VACCINE, 1997, 15 (09) : 944 - 947
  • [14] Radler S, 1991, VIRAL HEPATITIS LIVE
  • [15] Protective effect of inactivated hepatitis A vaccine against the outbreak of hepatitis A in an open rural community
    Shen, Yue-Gen
    Gu, Xie-Jun
    Zhou, Jian-Hong
    [J]. WORLD JOURNAL OF GASTROENTEROLOGY, 2008, 14 (17) : 2771 - 2775
  • [16] Long-term immunogenicity after single and booster dose of a live attenuated hepatitis A vaccine: Results from 8-year follow-up
    Wang, Xuan-Yi
    Xu, Zhi-Yi
    Ma, Jing-Chen
    von Seidlein, Lorenz
    Zhang, Yong
    Hao, Zhi-Yong
    Han, Oak Pil
    Zhang, Ying-Lin
    Tian, Mei-Ying
    Ouyang, Pei-Ying
    Zhang, Zhi-Yong
    han, Cg-Quan Han
    Xing, Zhan-Chun
    Chen, Ji-Chao
    [J]. VACCINE, 2007, 25 (03) : 446 - 449
  • [17] WANG ZS, 1989, B WORLD HEALTH ORGAN, V67, P171
  • [18] Incidence of hepatitis A in the United States in the era of vaccination
    Wasley, A
    Samandari, T
    Bell, BP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2005, 294 (02): : 194 - 201
  • [19] *WHO, 2000, WKLY EPIDEMIOL REC, V75, P37
  • [20] XU ZY, 2007, GLOB HEP C DEC 12 MI, pP47